pH-Controlled Terazosin Oral Liquid for Long-Term Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing terazosin hydrochloride formulations, particularly tablets and capsules, exhibit low dissolution rates and bioavailability, leading to absorption variability and non-compliance issues, especially in elderly and bedridden patients, and require unsafe compounding methods for alternative administration forms.
Innovation Solution
A stable oral liquid composition of terazosin or its pharmaceutically acceptable salt, formulated with pH modifiers and excipients, maintaining a pH range of 4.5 to 6.5, ensuring long-term stability and safety for geriatric and hospitalized patients.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If tablet or capsule forms of terazosin hydrochloride are used, then the dosage form is stable and easy to manufacture, but the disintegration time is long, dissolution rate is low, and bioavailability is reduced
Solution Approach 1:
The patent changes the physical state of the dosage form from solid (tablet/capsule) to liquid formulation, fundamentally altering dissolution characteristics. The liquid form eliminates the disintegration step required for solid dosage forms, providing immediate drug availability in solution while maintaining stability through proper formulation with excipients and pH control.
2Stability of the object's composition
If tablet or capsule forms of terazosin hydrochloride are used, then the dosage form is stable and easy to manufacture, but absorption variability increases and patient compliance decreases
Solution Approach 1:
The patent transitions from solid to liquid dosage form, which eliminates variability in disintegration and dissolution rates that affect absorption. The liquid formulation ensures consistent drug availability, providing reliable and predictable absorption profiles across different patients and administration conditions.
3Stability of the object's composition
If solid dosage forms (tablet/capsule) are used, then the formulation is stable, but patient compliance becomes difficult for elderly, bed-ridden, and dysphagic patients
Solution Approach 1:
The patent changes the dosage form from solid to liquid, making it easily ingestible for patients with swallowing difficulties. The liquid formulation can be administered to elderly, bed-ridden, and dysphagic patients without requiring chewing or swallowing capabilities, significantly improving ease of administration and patient compliance.
4Ease of operation
If liquid composition is developed for oral administration, then patient compliance and absorption consistency improve, but formulation stability becomes challenging to maintain
Solution Approach 1:
The patent employs excipients as intermediary substances that stabilize the liquid formulation. These excipients protect the drug substance from degradation, maintain proper pH levels, and ensure long-term stability of the liquid composition while preserving its ease of administration benefits.
Solution Approach 2:
The patent carefully controls formulation parameters including pH, temperature, and composition ratios to achieve and maintain stability. By optimizing these parameters, the liquid formulation achieves both improved patient compliance and long-term stability for extended shelf life.
Data Source
AI summary
The present invention relates to novel stable oral liquid composition of Terazosin and its pharmaceutically acceptable salt which is useful for treating symptomatic benign prostatic hyperplasia (BPH) and hypertension.